J. Corral

Once-Daily Atazanavir/Ritonavir Compared With Twice-Daily Lopinavir/Ritonavir, Each in Combination With Tenofovir and Emtricitabine, for Management of Antiretroviral-Naive HIV-1–Infected Patients: 96-Week Efficacy and Safety Results of the CASTLE Study

J. Absalon, J. Molina, G. Moyle, 2010, Journal of acquired immune deficiency syndromes.

Macrolide therapy is associated with lower mortality in community-acquired bacteraemic pneumonia.

William A. Mattingly, T. Wiemken, J. Ramirez, 2018, Respiratory medicine.

Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study

J. Molina, G. Moyle, M. Mancini, 2008, The Lancet.

Using Clinical Research Networks to Assess Severity of an Emerging Influenza Pandemic

Henrik Nielsen, L. Mathiesen, C. Leen, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia.

J. Milanowski, T. File, D. Górecka, 2011, The Journal of antimicrobial chemotherapy.

Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study

J. Molina, G. Moyle, M. Mancini, 2008, The Lancet.